The First FDA-Approved NASH Treatment Arrives After Almost Half a Century in the Making
The FDA has approved Madrigal Pharmaceuticals’ Rezdiffra™ (resmetirom) for nonalcoholic steatohepatitis (NASH). The approval is a watershed event, marking a historic turning point in the long-standing quest to find an effective treatment for the millions of Americans afflicted by this devastating condition. A targeted treatment for NASH has eluded pharmaceutical scientists for nearly a half century……